Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Int J Mol Sci. 2022 Mar 24;23(7):3538. doi: 10.3390/ijms23073538.
Epigenetic modifications rarely occur in isolation (as single "epigenetic modifications"). They usually appear together and form a network to control the epigenetic system. Cutaneous malignancies are usually affected by epigenetic changes. However, there is limited knowledge regarding the epigenetic changes associated with cutaneous lymphomas. In this review, we focused on cutaneous T-cell lymphomas such as mycosis fungoides, Sézary syndrome, and anaplastic large cell lymphoma. With regard to epigenetic changes, we summarize the detailed chemical modifications categorized into DNA methylation and histone acetylation and methylation. We also summarize the epigenetic modifications and characteristics of the drug for cutaneous T-cell lymphoma (CTCL). Furthermore, we discuss current research on epigenetic-targeted therapy against cutaneous T-cell lymphomas. Although the current method of treatment with histone deacetylase inhibitors does not exhibit sufficient therapeutic benefits in all cases of CTCL, epigenetic-targeted combination therapy might overcome this limitation for patients with CTCL.
表观遗传修饰很少是孤立发生的（作为单个“表观遗传修饰”）。它们通常一起出现并形成一个网络来控制表观遗传系统。皮肤恶性肿瘤通常受到表观遗传变化的影响。然而，对于与皮肤淋巴瘤相关的表观遗传变化知之甚少。在这篇综述中，我们专注于皮肤 T 细胞淋巴瘤，如蕈样真菌病、Sézary 综合征和间变大细胞淋巴瘤。关于表观遗传变化，我们总结了详细的化学修饰，分为 DNA 甲基化和组蛋白乙酰化和甲基化。我们还总结了皮肤 T 细胞淋巴瘤（CTCL）的表观遗传修饰和药物特征。此外，我们讨论了针对皮肤 T 细胞淋巴瘤的表观遗传靶向治疗的当前研究。尽管目前使用组蛋白去乙酰化酶抑制剂的治疗方法在所有 CTCL 病例中都没有显示出足够的治疗益处，但针对表观遗传的联合治疗可能会克服 CTCL 患者的这一局限性。
